Pool Erica R M, Dogar Omara, Lindsay Ryan P, Weatherburn Peter, Siddiqi Kamran
Brighton and Sussex University Hospitals NHS Trust, Brighton, UK.
Cochrane Database Syst Rev. 2016 Jun 13;2016(6):CD011120. doi: 10.1002/14651858.CD011120.pub2.
Tobacco use is highly prevalent amongst people living with HIV/AIDS (PLWHA) and has a substantial impact on morbidity and mortality.
To assess the effectiveness of interventions to motivate and assist tobacco use cessation for people living with HIV/AIDS (PLWHA), and to evaluate the risks of any harms associated with those interventions.
We searched the Cochrane Tobacco Addiction Group's Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and PsycINFO in June 2015. We also searched EThOS, ProQuest, four clinical trial registries, reference lists of articles, and searched for conference abstracts using Web of Science and handsearched speciality conference databases.
Controlled trials of behavioural or pharmacological interventions for tobacco cessation for PLWHA.
Two review authors independently extracted all data using a standardised electronic data collection form. They extracted data on the nature of the intervention, participants, and proportion achieving abstinence and they contacted study authors to obtain missing information. We collected data on long-term (greater than or equal to six months) and short-term (less than six months) outcomes. Where appropriate, we performed meta-analysis and estimated the pooled effects using the Mantel-Haenszel fixed-effect method. Two authors independently assessed and reported the risk of bias according to prespecified criteria.
We identified 14 studies relevant to this review, of which we included 12 in a meta-analysis (n = 2087). All studies provided an intervention combining behavioural support and pharmacotherapy, and in most studies this was compared to a less intensive control, typically comprising a brief behavioural intervention plus pharmacotherapy.There was moderate quality evidence from six studies for the long-term abstinence outcome, which showed no evidence of effect for more intense cessation interventions: (risk ratio (RR) 1.00, 95% confidence interval (CI) 0.72 to 1.39) with no evidence of heterogeneity (I(2) = 0%). The pooled long-term abstinence was 8% in both intervention and control conditions. There was very low quality evidence from 11 studies that more intense tobacco cessation interventions were effective in achieving short-term abstinence (RR 1.51, 95% CI 1.15 to 2.00); there was moderate heterogeneity (I(2) = 42%). Abstinence in the control group at short-term follow-up was 8% (n = 67/848) and in the intervention group was 13% (n = 118/937). The effect of tailoring the intervention for PLWHA was unclear. We further investigated the effect of intensity of behavioural intervention via number of sessions and total duration of contact. We failed to detect evidence of a difference in effect according to either measure of intensity, although there were few studies in each subgroup. It was not possible to perform the planned analysis of adverse events or HIV outcomes since these were not reported in more than one study.
AUTHORS' CONCLUSIONS: There is moderate quality evidence that combined tobacco cessation interventions provide similar outcomes to controls in PLWHA in the long-term. There is very low quality evidence that combined tobacco cessation interventions were effective in helping PLWHA achieve short-term abstinence. Despite this, tobacco cessation interventions should be offered to PLWHA, since even non-sustained periods of abstinence have proven benefits. Further large, well designed studies of cessation interventions for PLWHA are needed.
烟草使用在艾滋病毒/艾滋病感染者(PLWHA)中非常普遍,对发病率和死亡率有重大影响。
评估激励和协助艾滋病毒/艾滋病感染者戒烟干预措施的有效性,并评估与这些干预措施相关的任何危害风险。
我们于2015年6月检索了Cochrane烟草成瘾小组的专业注册库、Cochrane对照试验中心注册库(CENTRAL)、MEDLINE、EMBASE和PsycINFO。我们还检索了英国国家论文联合目录、ProQuest、四个临床试验注册库、文章的参考文献列表,并使用科学网搜索会议摘要,以及手工检索专业会议数据库。
针对艾滋病毒/艾滋病感染者戒烟的行为或药物干预的对照试验。
两位综述作者使用标准化电子数据收集表独立提取所有数据。他们提取了关于干预性质、参与者以及实现戒烟的比例的数据,并联系研究作者获取缺失信息。我们收集了长期(大于或等于六个月)和短期(小于六个月)结果的数据。在适当情况下,我们进行了荟萃分析,并使用Mantel-Haenszel固定效应方法估计合并效应。两位作者根据预先设定的标准独立评估并报告偏倚风险。
我们确定了14项与本综述相关的研究,其中12项纳入了荟萃分析(n = 2087)。所有研究都提供了行为支持和药物治疗相结合的干预措施,在大多数研究中,这与强度较低的对照进行了比较,通常包括简短的行为干预加药物治疗。六项研究提供了关于长期戒烟结果的中等质量证据,表明强化戒烟干预没有效果:(风险比(RR)1.00,95%置信区间(CI)0.72至1.39),没有异质性证据(I(2) = 0%)。干预组和对照组的长期戒烟合并率均为8%。11项研究提供了质量非常低的证据,表明强化戒烟干预在实现短期戒烟方面有效(RR 1.51,95% CI 1.15至2.00);存在中等异质性(I(2) = 42%)。短期随访时对照组的戒烟率为8%(n = 67/848),干预组为13%(n = 118/937)。为艾滋病毒/艾滋病感染者量身定制干预措施的效果尚不清楚。我们通过疗程数量和总接触时长进一步研究了行为干预强度的影响。尽管每个亚组中的研究较少,但我们未能发现根据任何强度指标存在效果差异的证据。由于不止一项研究未报告不良事件或艾滋病毒相关结果,因此无法进行计划中的分析。
有中等质量证据表明,联合戒烟干预措施在长期内为艾滋病毒/艾滋病感染者提供的结果与对照组相似。有质量非常低的证据表明,联合戒烟干预措施在帮助艾滋病毒/艾滋病感染者实现短期戒烟方面有效。尽管如此,仍应向艾滋病毒/艾滋病感染者提供戒烟干预措施,因为即使是短暂的戒烟期也已证明有益。需要针对艾滋病毒/艾滋病感染者戒烟干预措施开展进一步的大型、设计良好的研究。